NUVL Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Chartmill - Mentions: GTI TAIT CMCT APLT ...

Wondering what's happening in today's after-hours session?

a day ago - By: Nuvalent, Inc.

Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders

6 days ago - By: Nuvalent, Inc.

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

7 days ago - By: The Motley Fool - Mentions: HTFL NAMS CDTX PHVS ...

Biotech Stock Gets Booted in Latest Fund Update

7 days ago - By: Nuvalent, Inc.

Nuvalent Announces Pricing of Public Offering of Common Stock

8 days ago - By: Benzinga - Mentions: AIM GLMD VTGN VYNE ...

12 Health Care Stocks Moving In Monday's After-Market Session

8 days ago - By: Nuvalent, Inc.

Nuvalent Announces Public Offering of Common Stock

9 days ago - By: Benzinga

Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer

9 days ago - By: Stocktwits - Mentions: VTI

Why Did Nuvalent Stock Surge 15% Today?

9 days ago - By: Investor's Business Daily

Nuvalent Unveils A New Promise For Hard-To-Treat Lung Cancer

9 days ago - By: Nuvalent, Inc.

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

11 days ago - By: Nuvalent, Inc.

Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib

21 days ago - By: Nuvalent, Inc.

Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

a month ago - By: Nuvalent, Inc.

Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results

a month ago - By: Nuvalent, Inc.

Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025

a month ago - By: Nuvalent, Inc.

Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2 months ago - By: Nuvalent, Inc.

Nuvalent to Participate in the UBS 2025 Virtual Oncology Day

3 months ago - By: Nuvalent, Inc.

Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025

3 months ago - By: Nuvalent, Inc.

Nuvalent to Participate in the Cantor Global Healthcare Conference 2025

3 months ago - By: Nuvalent, Inc.

Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

4 months ago - By: The Motley Fool

Nuvalent (NUVL) Q2 R&D Up 65%

4 months ago - By: Nuvalent, Inc.

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

4 months ago - By: Nuvalent, Inc.

Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC

5 months ago - By: Yahoo Finance - Mentions: NUVB GS

JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans

5 months ago - By: Yahoo Finance - Mentions: MSFT

Nuvalent price target raised to $140 from $125 at Leerink

5 months ago - By: Yahoo Finance - Mentions: MSFT

Nuvalent price target raised to $130 from $110 at H.C. Wainwright

5 months ago - By: Nuvalent, Inc.

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

5 months ago - By: Nuvalent, Inc.

Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib

5 months ago - By: Nuvalent, Inc.

Nuvalent Appoints Christy Oliger to Board of Directors

7 months ago - By: Nuvalent, Inc.

Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

7 months ago - By: Nuvalent, Inc.

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

7 months ago - By: Yahoo Finance - Mentions: ERJ ACLX BKR META ...

Embraer announces Q1-end backlog of $26.4B

7 months ago - By: Yahoo Finance - Mentions: ADMA ACLX META ERJ ...

NUVALENT INC-A (NUVL) Stock News

NUVL Latest News, Press Relases and Analysis

Wondering what's happening in today's after-hours session?

Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

Biotech Stock Gets Booted in Latest Fund Update

Nuvalent Announces Pricing of Public Offering of Common Stock

12 Health Care Stocks Moving In Monday's After-Market Session

Nuvalent Announces Public Offering of Common Stock

Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer

Why Did Nuvalent Stock Surge 15% Today?

Nuvalent Unveils A New Promise For Hard-To-Treat Lung Cancer

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib

Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results

Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025

Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Nuvalent to Participate in the UBS 2025 Virtual Oncology Day

Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025

Nuvalent to Participate in the Cantor Global Healthcare Conference 2025

Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

Nuvalent (NUVL) Q2 R&D Up 65%

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC

JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans

Nuvalent price target raised to $140 from $125 at Leerink

Nuvalent price target raised to $130 from $110 at H.C. Wainwright

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib

Nuvalent Appoints Christy Oliger to Board of Directors

Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

Embraer announces Q1-end backlog of $26.4B

ADMA Biologics, Inc. (ADMA): Among Takeover Rumors Hedge Funds Are Buying